NASDAQ:RARE
Ultragenyx Pharmaceutical Inc. Stock News
$40.90
-0.320 (-0.776%)
At Close: May 10, 2024
Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update
05:00pm, Thursday, 27'th Jul 2023
NOVATO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri
Ultragenyx (RARE) Doses First Patients in Bone Disease Studies
09:23am, Friday, 07'th Jul 2023
Ultragenyx (RARE) announces dosing the first patients in its phase III studies evaluating setrusumab (UX143) in young adult and pediatric patients with osteogenesis imperfecta.
Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
05:00pm, Wednesday, 07'th Jun 2023
NOVATO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser
Ultragenyx (RARE) Posts Data From Osteogenesis Imperfecta Study
12:14pm, Tuesday, 06'th Jun 2023
Ultragenyx (RARE), along with partner Mereo BioPharma, announces encouraging data on mid-stage study evaluating setrusumab for patients with osteogenesis imperfecta.
Ultragenyx, Mereo shares gain after positive results from study of bone disorder treatment
09:30am, Tuesday, 06'th Jun 2023
Shares of Ultragenyx Pharmaceutical Inc. RARE, +6.67% and Mereo BioPharma Group PLC MREO, +11.43% gained premarket on Tuesday after the companies on Monday announced results from a study of setrusumab
Ultragenyx: A Promising Bet On Rare Genetic Disorder Therapies
07:15am, Monday, 29'th May 2023
Ultragenyx's pipeline boasts a diverse array of gene therapy candidates, including UX111, DTX401, DTX301, and UX701, offering transformative potential in the treatment of multiple rare genetic disease
Ultragenyx: Despite OI Trial Doubts, This Is A Robust Rare Disease Company
08:53am, Monday, 22'nd May 2023
Ultragenyx has a healthy rare disease product and pipeline. There are some issues with its next emerging catalyst.
TipRanks reveals the top 10 health care sector analysts of the past decade
08:20am, Sunday, 21'st May 2023
TipRanks' analyst ranking service ranks the top Wall Street firms of the past decade.
Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit
08:30am, Friday, 19'th May 2023
NOVATO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri
Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing
01:03pm, Thursday, 18'th May 2023
Ultragenyx (RARE) stock climbs 5% after the FDA agrees to a protocol amendment to the phase I/II study of GTX-102 in pediatric patients with Angelman syndrome.
Ultragenyx to Present at Bank of America's 2023 Health Care Conference
04:01pm, Friday, 05'th May 2023
NOVATO, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri
Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates
09:54am, Friday, 05'th May 2023
Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2023 Earnings Call Transcript
11:25pm, Thursday, 04'th May 2023
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q1 2023 Earnings Conference Call May 4, 2023 5:00 PM ET Company Participants Joshua Higa - Vice President and Head of Investor Relations Emil Kakkis - Fou
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
07:01pm, Thursday, 04'th May 2023
Ultragenyx (RARE) came out with a quarterly loss of $2.33 per share versus the Zacks Consensus Estimate of a loss of $1.97. This compares to loss of $2.19 per share a year ago.
Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update
04:05pm, Thursday, 27'th Apr 2023
NOVATO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for ser
